

## Notice Regarding Acquisition of Own Shares

(Acquisition of own shares pursuant to the provisions of Article 165, paragraph 2 of the Companies Act)

**Osaka, Japan, October 30, 2020** - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that it has resolved at a meeting of the Board of Directors held today, to acquire own shares pursuant to the provisions of Article 156 of the Companies Act, applied by replacing terms pursuant to the provisions of Article 165, paragraph 3 of said Act, as described below.

### 1. Reasons for the acquisition of own shares

Our financial policy during Phase 1 period (FY2020 to FY2024) of the New Medium-Term Business Plan “Shionogi Transformation Strategy 2030 (STS2030)”, announced on June 1, 2020, states that Shionogi is committed to aggressively investing in businesses to establish a sustainable growth model. We are also committed to implementing shareholder return policies flexibly using EPS, DOE, and ROE as the key performance indicators. As part of these capital policies, we will acquire own shares to strengthen shareholder returns and improve capital efficiency, which will lead to an increase in corporate value. Shionogi will work to further increase corporate value while securing the flexibility of capital.

### 2. Details of matters pertaining to the acquisition of own shares

Class of shares to be acquired	Common stock of the Company
Total number of shares to be acquired	9,500,000 shares (maximum) (3.1% of total outstanding shares [excluding treasury shares])
Total amount of acquisition cost	50 billion yen (maximum)
(1) Period of acquisition	November 1, 2020 to March 31, 2021
(2) Method of acquisition	Acquire in the open market through discretionary trading in Tokyo Stock Exchange

### (Reference) Treasury stockholding as of September 30, 2020

Total number of shares issued (excluding treasury shares)	310,242,495 shares
Number of treasury shares	1,343,670 shares

# Press Release



## **Forward-looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, inavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

## **For Further Information, Contact:**

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885